雄激素及其受体与多囊卵巢综合征

杨玫 林海伟 张宏权 徐小明* 陈曦*

doi:10.16098/j.issn.0529-1356.2018.01.023

PDF(213 KB)

解剖学报 ›› 2018, Vol. 49 ›› Issue (1) : 132-136. DOI: 10.16098/j.issn.0529-1356.2018.01.023

综述

雄激素及其受体与多囊卵巢综合征

杨玫^1,2 林海伟¹ 张宏权²徐小明^1* 陈曦^3*

作者信息 +

Androgen, androgen receptor and polycystic ovary syndrome

YANG Mei ^1,2 LIN Hai-wei¹ ZHANG Hong-quan² XU Xiao-ming ^1* CHEN Xi ^3*

Author information +

文章历史 +

摘要

多囊卵巢综合征（PCOS）是育龄期妇女常见的一种内分泌代谢性疾病，发病率为5%～10%，其发病机制尚未完全阐明。高雄激素血症是PCOS的突出特点，尤其是卵巢局部的高雄激素环境是导致PCOS的关键原因，因此对高雄激素形成这一特征性改变的研究成为阐明PCOS病因的重点所在。雄激素主要通过激活雄激素受体（AR）来发挥作用，故AR的作用不容忽视，我们着重就雄激素和AR在PCOS发病中的作用作一综述。

Abstract

Polycystic ovary syndrome (PCOS), with a prevalence of 5%-10%, is the most common endocrine and metabolic dysfunction of reproductive age women. However, the underlying mechanism has not been fully elucidated. Hyperandrogenism is the leading defect in PCOS patients, especially local androgen secretion by the ovary is the key element for PCOS pathogenesis. Androgen activates androgen receptor (AR), so the role of AR is an indispensable factor. This review focuses on the functions of androgen and AR in PCOS pathogenesis.

导出引用

杨玫林海伟张宏权徐小明陈曦. 雄激素及其受体与多囊卵巢综合征[J]. 解剖学报. 2018, 49(1): 132-136 https://doi.org/10.16098/j.issn.0529-1356.2018.01.023

YANG Mei LIN Hai-wei ZHANG Hong-quan XU Xiao-ming CHEN Xi. Androgen, androgen receptor and polycystic ovary syndrome[J]. Acta Anatomica Sinica. 2018, 49(1): 132-136 https://doi.org/10.16098/j.issn.0529-1356.2018.01.023

参考文献

［1］Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview［J］. Endocr Rev, 2002, 23(2): 175-200.

［2］Shah NA, Antoine HJ, Pall M, et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome［J］. J Clin Endocrinol Metab, 2008, 93(5): 1939-1945.

［3］Bennett NC, Gardiner RA, Hooper JD, et al. Molecular cell biology of androgen receptor signalling［J］. Int J Biochem Cell Biol, 2010, 42(6): 813-827.

［4］Walters KA, Middleton LJ, Joseph SR, et al. Targeted loss of androgen receptor signaling in murine granulosa cells of preantral and antral follicles causes female subfertility［J］. Biol Reprod, 2012,87(6): 151.

［5］Yang M, Du J, Lu D, et al. Increased expression of kindlin 2 in luteinized granulosa cells correlates with androgen receptor level in patients with polycystic ovary syndrome having hyperandrogenemia［J］. Reprod Sci, 2014, 21(6): 696-703.

［6］Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function［J］. Mol Endocrinol, 2010, 24(7): 1393-1403.

［7］Cheng XB, Jimenez M, Desai R, et al. Characterizing the neuroendocrine and ovarian defects of androgen receptor-knockout female mice［J］. Am J Physiol Endocrinol Metab, 2013, 305(6): E717-726.

［8］Wang RS, Chang HY, Kao SH, et al. Abnormal mitochondrial function and impaired granulose cell differentiation in androgen receptor knockout mice［J］. Int J Mol Sci, 2015, 16(5): 9831-9849.

［9］Gervásio CG, Bernuci MP, Silva-de-Sá MF, et al. The role of androgen hormones in early follicular development［J］. ISRN Obstet Gynecol, 2014, 2014: 818010.

［10］Zangmo R, Singh N, Kumar S, et al. Role of dehydroepiandrosterone in improving oocyte and embryo quality in IVF cycles［J］. Reprod Biomed Online, 2014, 28(6): 743-747.

［11］Narkwichean A, Maalouf W, Campbell BK, et al. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis［J］. Reprod Biol Endocrinol, 2013, 11: 44.

［12］Pierre A, Peigné M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome［J］. Hum Reprod. 2013, 28(3): 762-769.

［13］Bhide P, Dilgil M, Gudi A, et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimüllerian hormone than its counterpart in a normal ovary: an observational crosssectional study［J］. Fertil Steril, 2015, 103(2): 537-541.

［14］Pellatt L, Rice S, Mason HD. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high［J］. Reproduction, 2010, 139(5): 825-833.

［15］Yang M, Li J, An Y, et al. Effects of androgen on immunohistochemical localization of androgen receptor and connexin 43 in mouse ovary［J］. Tissue Cell, 2015, 47(5): 526-532.

［16］Tziomalos K, Katsikis I, Papadakis E, et al. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome［J］. Hum Reprod, 2013, 28(3): 785-793.

［17］Azziz, R., Carmina E, Dewailly D, et al., Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline［J］. J Clin Endocrinol Metab, 2006, 91(11): 4237-4245.

［18］Alpa ?és M, Luque-Ramírez M, Martínez-García M, et al. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome［J］. Fertil Steril, 2015, 103(3): 795-801.

［19］Qiao J, Feng HL. Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence［J］. Hum Reprod Update, 2011, 17(1): 17-33.

［20］Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS［J］. J Steroid Biochem Mol Biol, 2015, 145: 213-225.

［21］Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society［J］. Hum Reprod Update, 2014, 20(3): 334-352.

［22］Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome［J］. J Clin Endocrinol Metab, 2008, 93(11): 4456-4461.

［23］Walters KA. Role of androgens in normal and pathological ovarian function［J］. Reproduction, 2015, 149(4): R193-218.

［24］Franks S, Hardy K. Aberrant follicle development and anovulation in polycystic ovary syndrome［J］. Ann Endocrinol (Paris), 2010, 71(3): 228-230.

［25］Dewailly D, Catteau-Jonard S, Reyss AC, et al. The excess in 2-5 mm follicles seen at ovarian ultrasonography is tightly associated to thefollicular arrest of the polycystic ovary syndrome［J］. Hum Reprod, 2007, 22(6): 1562-1566.

［26］Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism［J］. Front Horm Res, 2013, 40: 22-27.

［27］Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis［J］. Hum Reprod, 2014, 29(6): 1117-1121.

［28］Wei D, Shi Y, Li J, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome［J］. Hum Reprod, 2017, 32(2): 354-361.

［29］Huang R, Zheng J, Li S, et al. Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome［J］. Acta Obstet Gynecol Scand, 2015, 94(5): 494-500.

［30］Cassar S, Teede HJ, Moran LJ,et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins［J］. Clin Endocrinol (Oxf), 2014, 81(6): 899-906.

［31］Ruan Y, Ma J, Xie X. Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis［J］. Endocr J, 2012, 59(7): 601-609.

［32］Rashidi B, Azizy L, Najmeddin F, et al. Prevalence of the insulin receptor substrate-1(IRS-1) Gly972Arg and the insulin receptor substrate-2(IRS-2) Gly1057Asp polymorphisms in PCOS patients and non-diabetic healthy women［J］. J Assist Reprod Genet, 2012, 29(2): 195-201.

［33］Christopoulos P, Mastorakos G, Gazouli M, et al. Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact［J］. Gynecol Endocrinol, 2010, 26(9): 698-703.

［34］Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth［J］. Int J Reprod Med, 2014, 2014: 719050.

［35］Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome［J］. Trends Mol Med, 2006, 12(7): 324-332.

［36］Wu S, Divall S, Nwaopara A, et al. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell［J］. Diabetes, 2014, 63(4): 1270-1282.

［37］Kyaw Tun T, McGowan A, Phelan N, et al. Obesity and Insulin Resistance Are the Main Determinants of Postprandial Lipoprotein Dysmetabolism in Polycystic Ovary Syndrome［J］. Int J Endocrinol, 2016, 2016: 9545239.

［38］Moran C, Arriaga M, Arechavaleta-Velasco F, et al. Adrenal androgen excess and body mass index in polycystic ovary syndrome［J］. J Clin Endocrinol Metab, 2015, 100(3): 942-950.

［39］Anderson AD, Solorzano CM, McCartney CR. Childhood obesity and its impact on the development of adolescent PCOS［J］. Semin Reprod Med, 2014, 32(3): 202-213.

［40］Spritzer PM, Lecke SB, Satler F, et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome［J］. Reproduction, 2015, 149(5): R219-R227.

［41］Cui N, Wang H, Wang W, et al. Impact of Body Mass Index on Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection Among Polycystic Ovarian Syndrome Patients［J］. Cell Physiol Biochem, 2016, 39(5): 1723-1734.

［42］Aghadavod E, Zarghami N, Farzadi L, et al. Evaluation of relationship between serum levels of anti-müllerian hormone, androgen, andinsulin resistant with retrieval oocytes in overweight patients with polycystic ovary syndrome［J］. Adv Biomed Res, 2015, 4: 76.